Evidence map›Paper›PMID 33577894›Full record

ArticleBiochemical pharmacology2021

Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency.

Cole Schonhofer, Jennifer Yi, Amanda Sciorillo, Kerstin Andrae-Marobela, Alan Cochrane, Marianne Harris, Zabrina L Brumme, Mark A Brockman, Karam Mounzer, Colin Hart and 4 more

Open access · greenAbstract read
In one paragraph

Article in Biochemical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Cole SchonhoferFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
Jennifer YiFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
Amanda SciorilloThe Wistar Institute, Philadelphia, PA, USA.
Kerstin Andrae-MarobelaDepartment of Biological Sciences, University of Botswana, Gaborone, Botswana.
Alan CochraneDepartment of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Marianne HarrisBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Mark A BrockmanFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
Karam MounzerJonathan Lax Immune Disorders Treatment Center, Philadelphia Field Initiating Group for HIV-1 Trials, Philadelphia, PA, USA.
Colin HartThe Wistar Institute, Philadelphia, PA, USA.
Kwasi GyampohThe Wistar Institute, Philadelphia, PA, USA.
Zhe YuanThe Wistar Institute, Philadelphia, PA, USA.
Luis J MontanerThe Wistar Institute, Philadelphia, PA, USA.
Ian TietjenFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada; The Wistar Institute, Philadelphia, PA, USA. Electronic address: itietjen@wistar.org.
The Wistar Institute · USSimon Fraser University · CAAIDS Vancouver · CAPhiladelphia Fight · USUniversity of Botswana · BWUniversity of Toronto · CA

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ronald G Collman · 1999 to 2026
$78.6M
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Canadian Institutes for Health Research PJT-153057NIAID NIH HHS P30 AI045008NIAID NIH HHS UM1 AI126620Wellcome TrustWellcome Trust 107752/Z/15/Z
6 · The paper itself

Abstract

While combination antiretroviral therapy (cART) durably suppresses HIV replication, virus persists in CD4

Indexed as

Cells, CulturedCell SurvivalCyclin-Dependent Kinase 9Dose-Response Relationship, DrugFlavonoidsHEK293 CellsHistone Deacetylase InhibitorsHistone DeacetylasesHIV-1HIV InfectionsHumansJurkat CellsLeukocytes, Mononucleartat Gene Products, Human Immunodeficiency VirusVirus LatencyCDK9 protein, humanCyclin-Dependent Kinase 9FlavonoidsHistone Deacetylase InhibitorsHistone Deacetylasestat Gene Products, Human Immunodeficiency VirusAntiviral agentCyclin-dependent kinase (CDK)FlavonoidHistone deacetylase (HDAC)Human immunodeficiency virus (HIV)Viral latency

Identifiers

PMID33577894
PMCPMC8052299
OpenAlexW3126713772

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.